Nirsevimab shows high efficacy in preventing severe RSV in infants

New real-world data indicates that Nirsevimab, a passive immunization prophylaxis, is highly effective at preventing severe cases of Respiratory Syncytial Virus (RSV) in infants. While RSV often causes mild symptoms in adults, it can lead to severe bronchiolitis or pneumonia in newborns due to their immature immune systems.

Unlike traditional vaccines, Nirsevimab utilizes long-acting monoclonal antibodies produced in a laboratory to provide immediate protection by blocking the virus in the airways. Studies show the treatment prevents approximately 80% to 90% of severe RSV cases and subsequent hospitalizations. The Standing Committee on Vaccination (STIKO) recommends this prophylaxis for all newborns and infants during their first RSV season. Data from Canada has further demonstrated the efficacy of this antibody prophylaxis in broad clinical application.